Hi Sumeet,

If you have rich sampling (and rich information on all parameters of interest) 
then one would not expect much difference between the individual parameter 
estimates with/without covariates in the model.
This does not make the covariate model meaningless, since future patients may 
be sparsely sampled, or the model may be used to identify subpopulations, or 
for predictions of future patients, etc.

When you say that pop predictions do not change, exactly what do you mean by 
that? The population typical value is not expected to change much (it may for 
categorical covariates with high impact) - the interpretation of the population 
parameter value has shifted from e.g. "median parameter value in population" 
(base model) to "median parameter value for a subject with typical covariate 
values".
This is because the covariate equations are generally centered around typical 
covariate values: We do not want the population parameter to represent CL for a 
subject with zero kilo body weight - had it been coded that way the population 
parameters would have changed dramatically.

So the question is rather if the typical parameter values for two subjects with 
different covariate values are different to a degree that it is important to 
account for (i.e. clinically relevant).
If we assume that you have body weight on CL, you can calculate e.g. the 2.5th 
and 97.5th percentiles of body weight in your population (or in another 
population or relevance).
And then you can calculate TVCL for these two different weights and compare to 
the typical body weight (e.g. 70 kg).
You may have for example this equation*:
TVCL=THETA(1)*(WT/70)**THETA(2)

Based on the point estimate and SE of THETA 2, you can then calculate percent 
change (from the typical 70 kg body weight) with point estimate and 95% CI, for 
each of the two extreme body weights.
And you can illustrate this in a so-called Forest plot (or tornado plot), for 
all covariate coefficients.

If the CI is wide, the data does not contain enough information to rule out 
clinical relevance (if you think the parameter in question is important - maybe 
abs rate is in some cases not, for examples).
But given that it has been selected by SCM, if the SE agrees (with LRT) CIs 
should not overlap with zero percent change.

If the CI is tight and with small change in the parameter, then that covariate 
relation can be concluded to be clinically irrelevant, despite being 
statistically significant. This may happen if you have many subjects in your 
data.
(Or if your limit for what is a relevant change is very wide)
In this case it may be justified leaving that covariate relation out of the 
final model.

Then of course, the fact that something was not statistically significant does 
not mean that the covariate effect is clinically irrelevant - it may just be 
that you do not have enough information.
To assess that you would need to use FREM or FFEM (instead of SCM) - but this 
is out of scope for your original question.

Best wishes

Jakob



*actually, for this example, THETA 2 may be fixed according to allometric 
principles, but let’s assume this is a large molecule and that allometry was 
not deemed suitable in this case, and therefore the covariate was tested in 
SCM, or otherwise estimated.

> On 29 Oct 2019, at 15:00, Singla, Sumeet K <[email protected]> wrote:
> 
> Hi!
>  
> I am performing stepwise covariate modeling using PsN feature in Pirana. I am 
> getting some covariates which are statistically reducing OFV significantly, 
> however, when I include those covariates in the PK model, the results I am 
> getting are exactly similar to what I am getting in my base model, i.e. there 
> is no difference in individual predictions or pop predictions or any other 
> diagnostic plots. So, does that mean I should move forward WITHOUT including 
> those covariates as they don’t seem to be explaining inter-individual 
> variability despite scm telling me that they are statistically significant?
>  
> Regards,
>  
> Sumeet K. Singla
> Ph.D. Candidate
> Division of Pharmaceutics and Translational Therapeutics
> College of Pharmacy | University of Iowa
> Iowa City, Iowa
> [email protected] <mailto:[email protected]>
> 518.577.5881

Reply via email to